-
Spain extends largest nuclear plant in policy U-turn
-
Croatian wildfire forces thousands to flee, injures dozens
-
Gill says 'huge honour' to lead India in 600th Test
-
Latest developments: Europe battles wildfires
-
Brazilian police recover Matisse works stolen in 2025
-
Is a new conflict brewing in northern Ethiopia?
-
Exiled Putin critic says push for peace put him in danger
-
UK firefighters 'under pressure' as multiple blazes rage
-
EU to study potential vaccine for Lyme disease: companies
-
ARKBRIDGE Reaches 50,000 Clients and Launches New Referral Rewards Program
-
Colombia vows to find all missing quake victims as rescue hopes fade
-
New wildfire forces evacuation of 500 people in France
-
Farage wins UK by-election as Count Binface claims 'moral victory'
-
ट्रोजन: एक अधिक खतरनाक राजनीतिक युग के लिए विशेष सुरक्षा
-
TROJAN: 더욱 위험해진 정치 시기를 위한 특별 보호 조치
-
『TROJAN』:政治情勢がより危険になる時代に向けた特別な保護策
-
《特洛伊木馬》:在政治局勢日趨險惡的時代,提供特別保護
-
برنامج «TROJAN»: حماية خاصة في ظل أوقات سياسية أكثر خطورة
-
TROJAN: спеціальний захист для більш небезпечних політичних часів
-
TROJAN: Special protection for a more perilous political era
-
Thai schools step up security after deadly shooting
-
Tanzid makes history as Bangladesh dominate first Australia Test
-
Thousands stranded as heavy rain kills at least four in Japan
-
Indonesia to close more than 750 state-owned enterprises
-
McIntosh bounces back with 400m medley win at Pan Pacs
-
US backs Japan over Putin trip to disputed islands
-
Farage declares victory as count still underway in UK by-election
-
'I want to be Eala': Philippine sensation sparks tennis boom at home
-
Australia probes three near-misses at Sydney Airport
-
US says lower oil prices, not Iran's nuclear program, are now top priority in war
-
Classy Tanzid puts Bangladesh in firm charge against Australia
-
Most Asian stocks track Wall St record as US data ease rate fears
-
Schwarber smacks two homers to power Philles' MLB Field of Dreams win
-
China's viral 'spicy strips' take a bite of global snack market
-
Pakistan's date workers toil through rising heat
-
Shelton does the double in Canada
-
New trend of injecting banned peptides to 'optimise' body
-
'Shock' gloves for US immigration agents fuel potential abuse fears
-
Eddie Jones senses Japan's time has come against Australia
-
New Zealand Football withdraws support for Infantino, urges review
-
UK vote count under way in Farage, Binface showdown
-
Hopes fade in Colombia as window to find quake survivors shuts
-
US, Mexico conduct security exercises near border
-
Trump announces tariffs of up to 100% on imported drones
-
Swiatek rolls past Rybakina for WTA Toronto title
-
Spieth among five sharing Memphis lead as PGA playoffs open
-
Vance says low oil prices are top US goal in Iran conflict
-
Boats rescue tourists as forest fire flames threaten Greek beaches
-
Hunt bags Euro sprint double, Ceh keeps discus title
-
Good vibes powering Djokovic return to Cincinnati
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
M.Qasim--SF-PST